Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nicotinamide riboside - ChromaDex

Next Previous
Drug Profile

Nicotinamide riboside - ChromaDex

Alternative Names: NIAGEN; Nicotinamide-beta-riboside; Nicotinamide-ribonucleoside; Nicotinamide-ribose; SRT-647

Latest Information Update: 19 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell University; Dartmouth College; Washington University
  • Developer ChromaDex; Ecole Polytechnique Federale de Lausanne.; Emory University; National Institutes of Health (USA); University of Cambridge; University of Iowa; Washington University
  • Class Amides; Analgesics; Antivirals; Nicotinic acids; Pyridines; Small molecules; Vitamins
  • Mechanism of Action Nicotinamide adenine dinucleotide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease; Ataxia telangiectasia; Cockayne syndrome; COVID 2019 infections; Heart failure; Mitochondrial myopathies; Pain; Retinal disorders

Most Recent Events

  • 19 Apr 2024 ChromaDex_10-K_SEC-filing_Dec-2023 : Updated patent info
  • 31 Dec 2023 ChromaDex has patent protection for nicotinamide riboside and its conjugates in USA
  • 31 Dec 2023 ChromaDex has patent protection for nicotinamide riboside in USA, China, Europe, India, Australia, Canada and Mexico (ChromaDex website, June 2016)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top